Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism.

Nelson B Watts,John P Bilezikian,Henry G Bone,Bart L Clarke,Douglas Denham,Michael A Levine,Michael Mannstadt,Munro Peacock,Jeffrey G Rothman,Tamara J Vokes,Mark L Warren, Shaoming Yin,Nicole Sherry,Dolores M Shoback

Journal of the Endocrine Society（2023）

引用 0|浏览16

暂无评分

摘要

6 years of rhPTH(1-84) treatment was associated with sustained improvements in biochemical parameters, a reduction in the percentage of patients with hypercalciuria, stable renal function, and decreased supplement requirements. rhPTH(1-84) was well tolerated; no new safety signals were identified.

查看译文

关键词

active vitamin D,bone turnover,calcium,hypoparathyroidism,mineral homeostasis,recombinant human parathyroid hormone (1-84)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要